Purpose: Prostate cancer is a heterogeneous genetic disease, and molecular methods for predicting prognosis in patients with aggressive form of the disease are urgently needed to better personalize treatment approaches. The objective was to identify host genetic variations in candidate steroidogenic genes affecting hormone levels and prostate cancer progression.
Introduction
Prostate cancer is clearly a major public health concern because it is the most common cancer in men and the second leading cause of cancer-related death in North America (1) . It is well established that androgen hormones play a central role in prostate cancer development and progression. Indeed, androgen deprivation therapy (ADT) is the cornerstone therapy for recurrent and metastatic prostate cancer (2, 3) . Furthermore, castration-resistant prostate cancer (CRPC), once thought to be hormone refractory, remains clearly driven by sex steroid hormones (4) . Even in a low-circulating testosterone environment, cancer cells generate potent intracellular hormones to support cancer growth and proliferation (5) . In addition, several studies sustain the role of sex steroid formation by prostate cancer cells that possess the enzymatic machinery to convert precursors into more potent hormones (5) (6) (7) . This reinforces the need to block intracellular steroidogenesis of prostatic cells. In metastatic settings, this concept is further reinforced with the advent of new compounds such as abiraterone acetate and MDV-3100, which targets, respectively, the CYP17 androgens' biosynthesis pathway and the androgen receptor, both effective for CRPC (8) (9) (10) (11) (12) .
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However, despite the improvement in survival of some patients with advanced prostate cancer, there are no available clinical prognostic molecular biomarkers of progression and mortality after treatment modalities such as radical prostatectomy, radiotherapy, hormonal manipulation, and chemotherapy.
In addition to tumor markers, common germline variations might determine tumor behavior or serve as informative biomarkers. In advanced disease state, studies have shown the impact of HSD17B4 genetic variations (13) and expression (14) relative to disease progression, and germline variations in SLCO2B1 and SLCO1B3 in response to palliative ADT therapy (15) . However, there is still a lack of molecular markers better defining aggressive and lethal prostate cancer. Recently, germline polymorphisms in SRD5A and HSD17B genes as well as deletions of UGT2B genes were shown to be associated with biochemical recurrence (BCR) in Caucasian and Taiwanese prostate cancer patients after radical prostatectomy (16, 17) . Such results are in agreement with a meaningful effect of inherited genetic variations in the androgenic pathway on prostate cancer recurrence and progression, regardless of race. Here, we sought to investigate the link between common germline variations in additional candidate steroidogenic genes on cancer progression and mortality, and to evaluate their relationships with circulating endogenous sex steroids.
Patients and Methods

Clinical data
The study included 526 Caucasians with localized prostate cancer who underwent radical prostatectomy as initial therapy and 601 Taiwanese men on ADT, described previously (16, 18) . Briefly, in the Caucasian cohort, PSA failure (n ¼ 130) after radical prostatectomy was defined as values of 0.3 mg/L or more (16; Table 1 ). In the Taiwanese ADT cohort (18) , treatment modalities are indicated in Table 2 . PSA nadir was defined as the lowest PSA value achieved during ADT treatment. The cause of death was obtained by matching patients' personal identification number with the official cause of death registry provided by the Department of Health, Executive Yuan (Taiwan, Republic of China). Prostate cancer-specific mortality (PCSM) was defined as the interval from the initiation of ADT to death from prostate cancer. The ACM was defined as the period from the initiation of ADT to death from any cause. Overall, 145 deaths were identified, and 101 of them died from prostate cancer. Participants provided written informed consent for the analysis of their genome and the Institutional Review Board approved the research protocol.
Genetic analysis
For genotyping, PCR amplifications were conducted on genomic DNA and products were analyzed by Sequenom iPLEX matrix-assisted laser desorption/ionization-time-offlight mass spectrometry. Polymorphisms in selected genes were chosen to explain most of the haplotype diversity. Indeed, a region covering all the exons, introns, and 5 kb of each of the 5 0 and 3 0 untranslated regions of selected genes was screened using a haplotype tagging SNPs (htSNP) strategy to maximize coverage (16, 17) .
A total of 112 SNPs were genotyped in Caucasians. Two SNPs were excluded because of a missing genotype frequency more than 5% (rs8041933 in CYP19A1 and rs9340941 in ESR1), and one SNP was excluded because of lack of genetic diversity (rs11968373 in ESR1). All SNPs were in HardyWeinberg equilibrium, except rs12900487, rs4441215, and rs2470152 in CYP19A1 and rs2982894 in ESR1. SNPs significantly associated with BCR, including those in SRD5A and HSD17B genes (17, 19) were successfully genotyped in Taiwanese men. There were not enough minor allele homozygotes to evaluate the impact of HSD17B2 rs1119933, rs1364287, rs2955162, and rs8059915 SNPs (17) . For both populations, the genotype call rate was in average 98% or more, and SNPs with a missing call rate 5% or more were excluded (n ¼ 6). Negative controls were present for every analysis and quality controls included 5% or more blind duplicates.
Measurement of steroid levels
Plasma samples were available from the Caucasian cohort collected on the morning of the surgical procedure. We excluded patients that received neoadjuvant hormonal treatment and those with missing genotype information for studied SNPs. Steroids were measured by validated gas chromatography/mass spectrometry or liquid chromatography/tandem mass spectrometry methods (16, 20) . Deuterated steroids were added to samples and quality controls were included in each
Translational Relevance
There are significant limitations in our ability to predict the progression and metastatic behavior of a patient's prostate cancer. Risk of disease progression differs greatly between individuals, and the variability in clinical outcome further emphasizes the need to find novel markers of progression. Sex steroid hormones are essential for the development and progression of prostate cancer. The purpose of this study was to assess the prognostic value of common genetic variants in key steroidogenic genes. Our findings support, in different ethnic groups and at different disease stages, the importance of CYP17A1, HSD17B2, and ESR1 as attractive prognostic molecular markers of prostate cancer progression. The use of understanding germline determinants of progression is that this could be used, along with known and established clinical factors, to prognosticate clinical course. Poor prognostic genetic factors could be used to select patients for future clinical trials and identify subgroups of patients that would most benefit from endocrine treatment. Therefore, our findings could lead to a more personalized approach to guide patient therapy based on molecular markers.
run. The lower limit of quantification is as follows: testosterone (0.03 ng/mL), dihydrotestosterone (DHT; 0.005 ng/mL), ADT (0.025 ng/mL), ADT-glucuronide (ADT-G; 1 ng/mL), and 3a-diol-3G and 3a-diol-17G (0.25 ng/mL), DHEA (0.1 ng/mL), DHEA-S (0.075 ug/mL), E 1 -S (0.075 ng/mL), E 1 (0.005 ng/mL), E 2 (0.001 ng/mL), androstenedione (4-dione; 0.05 ng/ mL), and androstenediol (5-diol; 0.05 ng/mL). Coefficients of variation for intra-and interassays for these methods were 10.0% or below, and accuracies for steroid hormones were as follows: testosterone (100.5%), DHT (103.5%), ADT (96.5%), ADT-G (99.5%), 3a-diol-3G (89.2%), 3a-diol-17G (100.2%), DHEA (96.13%), DHEA-S (99.9%), E 1 -S (100.45%), E 1 (106.9%), E 2 (103.15%), 4-dione (95.5%), and 5-diol (95.33%).
Statistical analysis
For association of SNPs with progression and PCSM and overall survival, individual htSNP was first considered using a model based on 3 categories (genomic model), namely To adjust for differences in the absolute levels of sex steroids, we calculated residuals of the natural logarithm of the hormone level regressed on age at blood donation and smoking status. The association with SNPs was conducted by regression of hormone residuals on each SNP independently for 4 models: recessive, dominant, codominant, and additive with 1 degree of freedom for the first 3 models, and 2 degrees of freedom for the additive model. We considered the association of a SNP with variation in hormone levels to be significant if the P value was <0.05. To facilitate the comparison between groups, we displayed the hormone level as untransformed data by using geometric mean and SEM. Statistical analyses were conducted using SAS Statistical Software version 9.2 (SAS Institute) and using PASW statistics version 17 (SPSS Inc.).
Results
A total of 109 htSNPs distributed across CYP17A1, CYP19A1, HSD3B, and ESR1 were studied in Caucasians (n ¼ 526) based on their role in hormone action, biosynthesis, and metabolism. Positive findings in these 4 genes, combined with previously identified markers in SRD5A1, SRD5A2, HSD17B2, HSD17B3, and HSD17B12 (17, 19) were subsequently tested in the Taiwanese ADT cohort to evaluate their potential impact on survival (n ¼ 32 SNPs).
Genetic analyses in Caucasians
Relative frequencies of SNPs in patients with cancer and their corresponding HRs (95% CI) are shown in Table 3 and 
Genetic analyses in Taiwanese ADT cohort
In agreement with the observations obtained in the Caucasian cohort, positive findings were also revealed for CYP17A1 in the Taiwanese ADT cohort. The CYP17A1 rs6162G variant was associated with mortality with a HR value of 1.69 (95% CI, 1.03-2.78; P ¼ 0.037; q ¼ 0.17). Interestingly, the rs4243229A in the HSD17B2 gene, the product of which inactivates sex steroids, was notably associated with an increased risk of death (HR 1.75; 95% CI, 1.22-2.51; P ¼ 0.002; q ¼ 0.03). Moreover, the ESR1 rs1062577A minor allele was similarly associated with worse outcome with an increased risk of mortality with a HR of 1.45 (95% CI, 1.02-2.07; P ¼ 0.038; q ¼ 0.17). Interestingly, the variant rs2257157C of HSD17B3, involved in hormone bioactivation, was also associated with an increased risk of death (HR 1.60, 95% CI: 1.11- Table 4 ). Most of these associations were also significant for PCSM in Taiwanese men (Supplementary Table S2 ).
Cumulative effects of adverse genotypes
When the cumulative effects of the adverse genotypes were investigated, significant associations with progression and overall survival were observed for patients with unfavorable genotypes in CYP17A1, ESR1, and HSD17B2 in both Caucasian and Taiwanese men (Fig. 1) . In Caucasians, the cumulative model includes CYP17 rs6162, the presence of one HSD17B2 risk allele (rs1364287, rs8059915, rs4243229, rs2955162, and rs1119933) and ESR1 rs1062577. In Taiwanese men, in addition to CYP17A1 and ESR1 variants, only the HSD17B2 alleles (rs4243229 and rs7201637) were included in the model because of very low frequency of the other SNPs in this population.
Relationship with endogenous sex-steroid hormones levels
The relationship of prognostic markers positive in both cohorts with circulating sex steroids was then assessed in the Caucasian cohort. Remarkably, CYP17A1 (rs6162), HSD17B2 (rs7201637), and ESR1 (rs1062577) variations were associated with significant changes in plasma steroid levels. The CYP17A1 rs6162 variation is associated with a 20% difference in DHEA-S levels (P ¼ 0.031). Although homozygotes for the minor allele are rare in Caucasians for the HSD17B2 rs7201637 variation (n ¼ 2), these patients display 50% lower 5-DIOL and DHT levels. The ESR1 rs1062577 variant correlated with reduced levels of E 1 -S and ADT-G. Additional hormone data in relation to genetic polymorphisms in CYP17A1, HSD17B2, and ESR1 are provided in Table 5 .
Discussion
There are clear unmet oncological needs to better predict prostate cancer progression, especially lethal prostate cancer, and so far, no prognostic markers fill this gap in knowledge. Host genetic variations in the well-characterized hormone biosynthetic and degradation pathways have not been studied systematically in terms of molecular markers associated with prostate cancer progression and none have been validated at different stages of the disease (13, 18, 22) . Here, we exposed several common inherited variations in CYP17A1, HSD17B2, and ESR1 associated with prostate cancer progression in 2 independent cohorts of patients and further showed their biologic association with plasma hormone levels.
The HSD17B2 gene is involved in steroids interconversion and controls C21, C19-, and C18-steroid bioavailability for nuclear receptor bindings and actions ( Fig. 2; refs. 23,  24) . Remarkably, variants in this gene, although being at different frequencies in the 2 ethnic groups studied herein, persist as prognostic markers associated with BCR, disease progression, and mortality following ADT [herein and ref. (17) ]. In Taiwanese men, the HSD17B2 rs4243229A [a variant more frequent in Asians than Caucasians; MAF; Figure 1 . Impact of germline variations in CYP17A1, ESR1, and HSD17B2 with prostate cancer progression. Prognostic SNPs located in ESR1, CYP17A1, and HSD17B2 were combined in relation to BCR in Caucasians (A) and all-cause mortality in Asians under ADT (B). Log rank (LR) P values are shown in each frame and HRs for each category are shown under both panels. (17)] was associated with shorter survival after adjustment for known prognostic factors and clearly defines a subgroup of patients at higher risk of progression and mortality. Although the impact of this polymorphism could not be assessed precisely on the steroid hormonal profile due to its lower frequency in Caucasians (no minor allele homozygote), other HSD17B2 markers influenced steroid hormone levels in patients with cancer, further reinforcing their potential role in cancer progression. On the basis of our preliminary data and those of others (24) (25) (26) (27) , we can speculate that genetic variations associated with progression in the HSD17B2 gene might lead to a loss-of-function in favor of the reductive pathway and accumulation of potent androgens and estrogens, thereby potentially modifying the course of the disease. Inversely, the observation of an association for the protective HSD17B2 rs7201637 with lower DHT in available homozygotes, suggests a more efficient inactivation of potent hormone by the 17bHSD type 2 enzyme, thereby plausibly reducing progression risk in these patients. Therefore, these positive markers, or any functional polymorphism in strong linkage, may significantly impair gene expression/function with subsequent modification in hormone levels that favor cell proliferation, and ultimately the survival of the patient. Together, data sustain a critical role of the HSD17B2 pathway as an important determinant in prostate cancer aggressiveness, progression, and survival (24) (25) (26) (27) (28) , and suggest that targeting this pathway and/or potentially the reverse HSD17B3/5 pathway (29, 30) might be beneficial for anticancer therapy (Fig. 2) .
Significant associations were also observed in both cohorts for SNPs in CYP17A1 and ESR1. CYP17A1 is one of the early steps in the biosynthesis of sex steroids and the molecular target of abiraterone that improves survival after docetaxel treatment in patients with CRPC (8) . The CYP17A1 rs6162 variation was associated with prostate cancer progression and mortality herein, further reinforcing the importance of this critical pathway in cancer progression at numerous disease stages and in different ethnic groups. In support, 3 previous studies have looked at the impact of CYP17A1 on prostate cancer outcomes (31) (32) (33) . In agreement with our findings, in these studies, the presence of polymorphisms in CYP17A1 was also associated with disease progression and mortality in Caucasians and Asians (31-33; Table 6 ). Overall, our data combined with previous observations (31) (32) (33) clearly support a major role of CYP17A1 on cancer progression after diagnosis. Moreover, we showed that the presence of CYP17A1 SNPs is further associated with altered levels of circulating DHEA-S in Caucasians, which likely modify steroid precursor levels available for intracrine conversion to more potent hormones in tissues and prostatic cells. It is unclear whether this modification in DHEA-S levels is caused by an altered enzyme activity or expression in target cells and/or feedback mechanism on the hypothalamic-pituitary-adrenal axis or any other unknown physiologic process. Interestingly, germline variations of CYP17A1, associated with outcomes herein and in previous studies (31, 32) , are mostly located in the promoter region and exon 1 raising the possibility of a functional impact on transcriptional activity of the gene. Further study is clearly needed to decipher the molecular mechanism(s) underlying this pathophysiologic association. Ryan and colleagues showed that baseline levels of androstenedione might be predictive of ketoconazole response in metastatic patients (34) . Therefore, in view of data presented here, the high frequency of the CYP17A1 rs6162 ($50%) and its association with circulating DHEA-S levels, it would be relevant to evaluate, in future studies, the predictive and prognostic impact of CYP17A1 variations on abiraterone response and outcome.
Moreover, the ESR1 rs1062577 variant associated with progression also seems to affect the circulating hormone profile, with carriers of the minor allele showing reduced systemic E 1 -S and ADT-G levels. A previous report suggests that E 1 -S is associated with prostate cancer aggressiveness, being positively associated with margin status, stage, and PSA levels (35) . Accordingly, we also observed a correlation between E 1 -S and margin status, with higher levels being associated positive margins (P ¼ 0.007, not shown). A previous extensive evaluation of ESR1 genetic variations was also conducted on cancer aggressiveness and efficacy of ADT; however, to our knowledge, the rs1062577 variant was not specifically evaluated in previous studies (28, 36) . Another group reported that this common SNP (rs1062557) might affect the binding capacity of miR-186 based on in silico analysis (37) .
Interestingly, the HSD17B3 rs2257157 SNP was associated with cancer-related death in Taiwanese men on ADT, whereas the CYP19A1 rs1870050 SNP was associated with better survival. This variation is located in the promoter region of CYP19A1 encoding the aromatase enzyme, a ratelimiting step in estrogens production from androgens. Remarkably, the CYP19A1 rs1870050 was associated with progression in Caucasians in agreement with previous association displaying a shorter time to progression in a cohort of men on ADT composed mainly of Caucasians (13) . Differences in outcome between populations are perhaps linked to different haplotypes tagged by these SNPs in diverse ethnic groups. Nevertheless, validation of these 2 latter markers in cohorts with similar clinical and pathologic characteristics is still required to fully ascertain their role in cancer progression.
The importance of inherited genetic variations in the steroidogenic pathways is not surprising because they contribute to the maintenance and bioavailability of active hormones in multiple target organs despite hormonal therapy (5, 6) . Nevertheless, most of these htSNPs, or their associated SNPs, have not been biochemically studied and their functionality still remains undefined. As such, limitations of the study are mainly related to the scarcity of the functional data for positive markers and lack of additional cohorts for definitive validation at each disease stage.
Strengths of the study include a significant number of patients, a candidate gene approach, the high plausibility of the association based on the biologic function of selected candidate pathways, repeated associations in 2 genetically divergent ethnic groups, an impact on circulating steroid levels associated with positive markers, and clinical endpoints including both progression and survival. Finally, results further underscore the need to examine the potential relationship between prognostic markers and tissue hormone levels to better understand their physiologic consequence and contribution to cancer progression.
Data clearly emphasizes the biologic significance of the HSD17B2, CYP17A, and ESR1 pathways in prostate cancer progression and provides promising prognostic candidates for explaining differences in clinical outcomes. The assessment of host genetic variations in key steroidogenic pathways, such as those identified herein, represent additional evidence that sex steroids are likely involved throughout all stages of disease progression including a castrate environment. Furthermore, findings support the seed and soil hypothesis in which germline variations in steroidogenic pathways influence the hormonal microenvironment to which cancer cells are exposed and a subsequent impact on prostate cancer proliferation, recurrence, and progression. These molecular markers may improve prognostication of prostate cancer, lead to a better patient stratification in future clinical trials, targeting therapeutic interventions to optimize hormonal manipulation in patients with a high risk of recurrence, and more likely to benefit from treatment. However, before such translational advance is made, additional investigations are required to fully characterize the underlying biologic mechanisms driving the positive associations of inherited germline variations in those key genes on steroid hormone levels, progression, and survival. In conclusion, in combination with tumor changes, the major challenge will be to decipher precisely which sets of inherited gene combinations are associated with favorable and adverse outcomes to ultimately personalize the management of prostate cancer. E. L evesque, C. Guillemette
